Apple Unveils AFM 3: Breaking the On-Device AI Parameter Limit with NAND Flash
Apple’s third-generation foundation models, announced at the 2026 Worldwide Developers Conference, introduce a breakthrough in on-device AI by replacing DRAM with NAND flash for storing 20-billion-parameter models, according to a June 8, 2026, Apple Machine Learning Research paper. This shift allows enterprise architects to deploy complex agentic workloads locally without cloud dependency, though deployment details remain under wraps.
How Does Apple’s AFM 3 Architecture Differ from Traditional On-Device AI Models?
Traditional on-device AI models require all parameters to fit in DRAM, limiting their size. Apple’s AFM 3 Core Advanced bypasses this constraint by storing its full 20-billion-parameter weight set in NAND flash, as detailed in the company’s architecture paper. Instead of loading all parameters into memory, the model uses a “prediction-and-load” mechanism: a smaller model predicts which “experts” (components of the AI) to load into DRAM based on the input prompt. This approach avoids the bandwidth limitations of moving weights between NAND and DRAM during inference.
“You can’t put 20B parameters in RAM at any reasonable precision,” wrote Awni Hannun, a researcher at Anthropic and former Apple research scientist, on X. “To make it work they are using pretty exotic architecture by today’s standards.”
What Are the Technical Implications of Using NAND Flash for AI Models?
The AFM 3 Core Advanced model dynamically scales its active parameter count from 1 billion to 4 billion per task, drawing from the 20-billion-parameter pool in flash. This “Instruction-Following Pruning” (IFP) method ensures only necessary components are loaded into DRAM, reducing memory overhead. However, the architecture paper provides limited details on energy consumption, thermal constraints, or memory bandwidth—key factors for on-device performance, according to Marco Abis, a developer of the Ziraph AI profiler for Apple silicon.
“Energy, memory bandwidth, thermal? Not in the docs,” Abis wrote on X. “A notable gap, given those decide most of on-device performance.”
What Does This Mean for Enterprise Architects Evaluating Agentic Workloads?
Enterprises now face a new architectural choice: simpler tasks can run locally on-device, while complex agentic workloads route to the server-based AFM 3 Cloud Pro model, which operates on Nvidia GPUs within Google Cloud’s infrastructure. Apple’s Private Cloud Compute framework guarantees data privacy for these server-side operations, but the dependency on Google Cloud remains a point of contention for organizations requiring strict compliance controls.

“The private/cloud boundary is now an architectural decision, not a default,” noted the research paper. However, Apple has not disclosed whether on-device requests automatically offload to the cloud or if developers can track this routing, creating ambiguity for compliance teams.
What Challenges Remain for Apple’s On-Device AI Strategy?
While the AFM 3 Core Advanced represents a significant leap, its real-world viability hinges on Apple’s upcoming summer technical report, which is expected to include benchmarks and deployment constraints. Without transparency on energy efficiency, thermal management, or offloading policies, enterprises may hesitate to adopt the technology at scale.

“What Apple has and hasn’t disclosed” remains a critical question, as highlighted by Abis. “Not all the information is currently available.”
How Does This Compare to Competing On-Device AI Solutions?
Other companies, such as Meta and Google, have explored similar approaches to reduce on-device memory usage, but Apple’s integration of NAND flash for full-model storage is unique. For example, Meta’s Llama models rely on quantization to shrink parameter counts, while Google’s Gemini series emphasizes cloud-based scalability. Apple’s solution, however, prioritizes local execution without compromising model size—a trade-off that could redefine on-device AI capabilities.
As Apple prepares to release its full technical report, the AFM 3 family signals a pivotal shift in AI deployment strategies, blending local autonomy with cloud scalability. For now, the company’s innovation underscores the growing importance of hardware-software co-design in overcoming the “memory wall” that has long constrained on-device AI.
Keep reading
- Blizzard Workers Unite: A Community Beyond Corporate Walls
- Sony Shuts Down The Last of Us Part II Multiplayer Mod
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
- Why the iPhone 18 Pro Max Sold in the US Skips Apple's New Modem (daybreakwire.com)